

ASX ANNOUNCEMENT

27 July 2020

Respiri Provides CY21 Revenue Guidance of \$6-\$8 million

Respiri Limited (ASX:RSH) (“Respiri” or the “Company”), an eHealth SaaS Company supporting respiratory health management, today provides an update on revenue expectations for the calendar year ended 31 December 2021 (CY21). The Board of Directors has finalised a review of the revenue generating commercial contracts that have been progressively signed during FY20, particularly the recently announced exclusive international pharmacy sales/marketing, distribution & logistics agreement with Cipla and also the market dynamics forecast to drive wheezo® market penetration. As a result, the Company anticipates CY21 product revenues comprising wheezo® device sales and associated Software as a Service (SaaS) subscription revenues to be \$6-\$8 million.

Mr Marjan Mikel, CEO of Respiri Limited said “In discussions with our partners it has been apparent that respiratory disease patients such as asthmatics have a heightened level of awareness in effectively managing their disease, and in particular the potential for more serious adverse events from coronavirus (COVID-19) infections. In formulating our CY21 guidance, the Board has considered a number of factors, including the resilience of the pharmacy channel from disruption during the COVID-19 pandemic in Australia, owing to its status as an essential service, along with Cipla’s active account management of 4,000 of these pharmacies and strong commercial relationships with the major pharmacy banner groups and chains.”

Mr Mikel continued “Equally, General Practice and other physician management of patients with asthma will continue during these difficult times as we are witnessing with the recruitment of Health Care Practitioners to participate in the wheezo® Patient Experiential Program (PEP), which is still moving ahead as planned. We look forward to updating our investors throughout the year on our progress in achieving these revenue goals, noting our guidance is predicated on the maintenance of Australian pharmacy operations and supply throughout the pandemic.”

- ENDS -

For further information, investors and media please contact:

Mr Marjan Mikel
 CEO & Managing Director
 Respiri Limited
 P: +61 408 462 873
 E: marjan@respiri.co

Mr Nicholas Smedley
 Executive Chairman
 Respiri Limited
 P: +61 447 074 160
 E: nicholas@respiri.co

This ASX announcement dated 27 July 2020 has been authorised for release by the Board of Directors of Respiri Limited.

About Respi Limited

Respi is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. The only platform of its kind, the flagship wheezo® product employs machine learning to provide personalised feedback and education based on the user's personal health data correlated with environmental factors, and enables the sharing of that data, anytime, anywhere with caregivers, physicians and other health care professionals.

Respi's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respi Limited's operations are based in Melbourne, Australia.

For additional information about Respi and its products, please visit www.respi.co

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respi current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respi only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.